A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED) - VGN-TED-302

Start Date31 Oct 2023

Sponsor / Collaborator-

NCT06112340

/ RecruitingPhase 2/3

A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.

Start Date11 Oct 2023

Sponsor / Collaborator

Sling Therapeutics, Inc.Startup

NCT05276063

/ Active, not recruitingPhase 2/3

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

Start Date01 Jul 2022

Sponsor / Collaborator

Sling Therapeutics, Inc.Startup

100 Clinical Results associated with Linsitinib

100 Translational Medicine associated with Linsitinib

100 Patents (Medical) associated with Linsitinib

181

Literatures (Medical) associated with Linsitinib

20 Dec 2024·JCI Insight

Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway

Article

Author: Rajaii, Fatemeh ; Li, Emily ; Han, Jeong ; Kim, Soohyun ; Belday, Karan ; Blackshaw, Seth ; Mahoney, Nicholas ; Kim, Dong Won

Despite recent advances in the treatment of thyroid eye disease thyroid-related eye disease (TED), marked gaps remain in our understanding of the underlying molecular mechanisms, particularly concerning the insulin-like growth factor-1 receptor (IGF-1R) pathway. To dissect the pathophysiology of TED, we used single-nucleus RNA-Seq to analyze orbital fat specimens from both patients with TED and matched individuals acting as controls. The analysis demonstrated a marked increase in the proportion of fibroblasts transitioning to adipogenesis in the orbital fat of patients with TED compared with that in control patients. This was associated with diverse alterations in immune cell composition. Significant alterations in the IGF-1R signaling pathway were noted between TED specimens and those from control patients, indicating a potential pathological mechanism driven by IGF-1R signaling abnormalities. Additionally, our data showed that linsitinib, a small-molecule inhibitor of IGF-1R, effectively reduced adipogenesis in TED orbital fibroblasts in vitro, suggesting its potential utility as a therapeutic agent. Our findings reveal that, beyond immune dysfunction, abnormal IGF-1R signaling leading to enhanced adipogenesis is a crucial pathogenic mechanism in TED.

01 Dec 2024·The FEBS Journal

Catalytic activities of wild‐type C. elegansDAF‐2 kinase and dauer‐associated mutants

Article

Author: Ahmed, Sultan ; Miller, W. Todd ; Krishnan, Harini ; Hubbard, Stevan R.

DAF‐2, the Caenorhabditis elegans insulin‐like receptor homolog, regulates larval development, metabolism, stress response, and lifespan. The availability of numerous daf‐2 mutant alleles has made it possible to elucidate the genetic mechanisms underlying these physiological processes. The DAF‐2 pathway is significantly conserved with the human insulin/IGF‐1 signaling pathway; it includes proteins homologous to human IRS, GRB‐2, and PI3K, making it an important model to investigate human pathological conditions. We expressed and purified the kinase domain of wild‐type DAF‐2 to examine the catalytic activity and substrate specificity of the enzyme. Like the human insulin receptor kinase, DAF‐2 kinase phosphorylates tyrosines within specific YxN or YxxM motifs, which are important for recruiting downstream effectors. DAF‐2 kinase phosphorylated peptides derived from the YxxM and YxN motifs located in the C‐terminal extension of the receptor tyrosine kinase, consistent with the idea that the DAF‐2 receptor may possess independent signaling capacity. Unlike the human insulin or IGF‐1 receptor kinases, DAF‐2 kinase was poorly inhibited by the small‐molecule inhibitor linsitinib. We also expressed and purified mutant kinases corresponding to daf‐2 alleles that result in partial loss‐of‐function phenotypes in C. elegans. These mutations caused a complete loss of kinase function in vitro. Our biochemical investigations provide new insights into DAF‐2 kinase function, and the approach should be useful for studying other mutations to shed light on DAF‐2 signaling in C. elegans physiology.

01 Dec 2024·European Journal of Pharmaceutical Sciences

In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants

Article

Author: Kahma, Helinä ; Neuvonen, Mikko ; Cai, Weimin ; Paludetto, Marie-Noëlle ; Kurkela, Mika ; Jin, Shasha ; Backman, Janne T. ; Backman, Janne T ; Xiang, Xiaoqiang

OBJECTIVEThis study aimed to evaluate the cytochrome P450 (CYP)-mediated drug-drug interaction (DDI) potential of kinase inhibitors with warfarin and direct oral anticoagulants (DOACs).METHODSAn in vitro CYP probe substrate cocktail assay was used to study the inhibitory effects of fifteen kinase inhibitors on CYP2C9, 3A, and 1A2. Then, DDI predictions were performed using both mechanistic static and physiologically-based pharmacokinetic (PBPK) models.RESULTSLinsitinib, masitinib, regorafenib, tozasertib, trametinib, and vatalanib were identified as competitive CYP2C9 inhibitors (K_i = 1.4, 1.0, 1.1, 3.8, 0.5, and 0.1 μM, respectively). Masitinib and vatalanib were competitive CYP3A inhibitors (K_i = 1.3 and 0.2 μM), and vatalanib noncompetitively inhibited CYP1A2 (K_i = 2.0 μM). Moreover, linsitinib and tozasertib were CYP3A time-dependent inhibitors (K_I = 26.5 and 400.3 μM, k_inact = 0.060 and 0.026 min^-1, respectively). Only linsitinib showed time-dependent inhibition of CYP1A2 (K_I = 13.9 μM, k_inact = 0.018 min^-1). Mechanistic static models identified possible DDI risks for linsitinib and vatalanib with (S)-/(R)-warfarin, and for masitinib with (S)-warfarin. PBPK simulations further confirmed that vatalanib may increase (S)- and (R)-warfarin exposure by 4.37- and 1.80-fold, respectively, and that linsitinib may increase (R)-warfarin exposure by 3.10-fold. Mechanistic static models predicted a smaller risk of DDIs between kinase inhibitors and apixaban or rivaroxaban. The greatest AUC increases (1.50-1.74) were predicted for erlotinib in combination with apixaban and rivaroxaban. Linsitinib, masitinib, and vatalanib were predicted to have a smaller effect on apixaban and rivaroxaban AUCs (AUCR 1.22-1.53). No kinase inhibitor was predicted to increase edoxaban exposure.CONCLUSIONSOur results suggest that several kinase inhibitors, including vatalanib and linsitinib, can cause CYP-mediated drug-drug interactions with warfarin and, to a lesser extent, with apixaban and rivaroxaban. The work provides mechanistic insights into the risk of DDIs between kinase inhibitors and anticoagulants, which can be used to avoid preventable DDIs in the clinic.

News (Medical) associated with Linsitinib

14 Jan 2025

·www.fiercebiotech.com

Sling\'s oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3

Convenience is one area Sling Therapeutics may have an edge over the incumbent in thyroid eye disease. \n Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) trial, teeing the biotech up to run a confirmatory study of its ex-Astellas asset. But a cross-trial comparison suggests Amgen’s blockbuster may have the advantage on the efficacy front.Astellas studied the small-molecule IGF-1R inhibitor linsitinib as a cancer treatment. However, with the anti-IGF-1R antibody Tepezza showing the benefits of targeting the receptor in TED, Sling spied a chance to use linsitinib in the eye disease. The biotech launched with $35 million to run a phase 2b trial in TED, a complication of Graves’ disease that causes the eyes to bulge, in 2022.About 18 months later, Sling has evidence linsitinib works in TED. Investigators randomized 90 patients to receive one of two doses of linsitinib or placebo. After 24 weeks, 52% of people on the high dose had a big enough reduction in eye bulging to meet the response criteria.The response rate was significantly higher than in the placebo group, causing the high dose to achieve the primary endpoint. Sling made no mention of the performance of the low dose. The biotech is now preparing to start a confirmatory phase 3 trial this year. Horizon Therapeutics, which brought Tepezza to market before selling up to Amgen, reported a higher response rate in its phase 3 program. After eight infusions across 24 weeks, the response rates in the two Tepezza trials were (PDF) 71% and 83%. Cross-trial comparisons can be misleading, but the available data suggest Sling may need to focus on areas other than efficacy to compete.Convenience is one area Sling may have an edge over the incumbent. Tepezza patients receive 60- to 90-minute infusions every three weeks. Linsitinib is taken orally twice a day. Amgen began a phase 3 trial of a subcutaneous formulation of Tepezza last year, positioning it to potentially free patients from lengthy infusions in the future.Safety and tolerability is another potential battleground. In Tepezza’s phase 3 program, 10% of patients on the drug developed hearing impairment, a catch-all term for conditions such as deafness and tinnitus. Sling said no drug-related hearing impairment was reported in its trial, although there was one unrelated report, and the placebo-adjusted tinnitus rate was 0%. Hyperglycemia was rarer than for Tepezza, too.Sling saw elevated liver enzymes, but they resolved quickly and caused no signs of drug-induced injury, leading the biotech to conclude linsitinib was well tolerated. The planned phase 3 trial will shed more light on the molecule’s safety and efficacy profile and potentially position Sling to challenge Amgen for the TED market.

$Sling\'s oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3$

Phase 3Clinical ResultPhase 2

14 Jan 2025

·www.prnewswire.com

Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease

- Linsitinib is the first and only oral small molecule therapy to establish statistical and clinical significance in Thyroid Eye Disease (TED) - Phase 2b/3 LIDS trial met primary endpoint of proptosis reduction with statistical significance at 150mg BID dose - Linsitinib was well-tolerated particularly in IGF-1R areas of interest such as hearing impairment, glycemic changes, and menstrual cycle changes - Confirmatory Phase 3 trial on track to commence in 2025 ANN ARBOR, Mich., Jan. 14, 2025 /PRNewswire/ -- Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe TED. Linsitinib, Sling's lead product candidate, is a convenient oral small molecule, taken twice-daily, in clinical development for TED. Linsitinib works by inhibiting the validated IGF-1R target and has an established safety profile through treatment of more than 900 patients across fifteen clinical trials in multiple disease areas. "The positive data from this trial establish the clinical significance of linsitinib and represent the first ever successful clinical trial of an oral small molecule for the treatment of TED," said Ryan Zeidan, Ph.D., President and Chief Executive Officer of Sling Therapeutics. "We believe linsitinib can be a potential new treatment option that could enable a broader number of physicians across multiple therapeutic disciplines to treat patients diagnosed with TED. We are excited to continue our clinical program and are on track to initiate our confirmatory Phase 3 registrational trial later this year." Trial Overview and Topline Results The LIDS Phase 2b/3, randomized, double-masked, placebo-controlled study was designed to evaluate the safety, pharmacokinetics, and efficacy of linsitinib in patients with active, moderate to severe TED. The primary endpoint of the study was the percentage of subjects who were proptosis responders at week 24, defined as at least a two-millimeter reduction in proptosis from baseline. The LIDS trial enrolled 90 patients who were randomized 1:1:1 and received either linsitinib 150mg BID, linsitinib 75mg BID, or placebo for 24 weeks. The trial was conducted globally at 35 sites in five countries. The LIDS trial met its primary endpoint with statistical significance for the 150mg BID dose. Linsitinib in this trial validated the safety profile seen in the prior oncology studies and importantly demonstrated a favorable safety profile on key adverse events (AEs) of interest for the IGF-1R target such as hearing impairment, hyperglycemia, and menstrual cycle changes. Additionally, no QTc prolongation was observed in any patient with rigorous ECG monitoring throughout the study. Key Topline Data: Statistically Significant Proptosis Responder Rate (PRR): PRR was statistically significant and clinically meaningful at the 150mg BID dose, with a PRR of 52% (p = 0.01) at Week 24. Consistent Safety Data, No Drug-Related Hearing Impairments: Linsitinib was well-tolerated and consistent with the safety profile of the previous 15 linsitinib clinical trials, which now includes more than 900 patients in multiple disease areas. Key AE data from the 150mg BID arm include: No drug-related hearing impairment reported (1 unrelated report out of 29 patients) 0% tinnitus placebo-adjusted rate 3% rate of hyperglycemia (1 report out of 29 patients with no intervention required) 0% menstrual cycle changes reported Treatment emergent AEs greater than or equal to 10%: diarrhea (20.7%), headache (20.7%), nausea (20.7%), fatigue (17.2%), ALT increase (17.2%), hyperhidrosis (13.8%), AST increase (10.3%), and muscle spasms (10.3%) Hepatic transaminases were all quickly resolved and not associated with any elevations of total bilirubin, alkaline phosphatase, hepatic dysfunction, or other signs or symptoms of drug-induced liver injury The majority of AEs were either mild or moderate, reversible, and quickly resolved upon treatment pause or discontinuation consistent with a shorter half-life treatment No QTc prolongation was observed in any patient with rigorous monitoring throughout the study "TED is a debilitating auto-immune disorder with limited options available for patients today. Patients must currently choose between an invasive orbital surgery or eight infusions over 24 weeks, which can be inconvenient and time-consuming and pose serious potential risks," said Raymond Douglas, M.D., Ph.D., Professor at Cedars-Sinai Medical Center and KOL and lead investigator in previous TED trials, as well as Chief Scientific Officer at Sling Therapeutics. "In this trial, patients demonstrated significant improvement in disease with no drug-related hearing impairments or significant hyperglycemia. These side effects are the largest barriers for current medical treatments, making linsitinib an important potential new therapy for patients with TED. As a practicing physician, it makes sense to start a new patient's treatment journey with an oral therapy that shows an early response that increases over time." The Company is engaging with regulatory authorities to discuss the confirmatory Phase 3 trial design, which is on track to commence in 2025. Full results of this Phase 2b/3 trial will be presented at an upcoming medical conference. About Linsitinib Linsitinib is a convenient oral small molecule, taken twice-daily and with a short half-life, in clinical development for thyroid eye disease (TED). Linsitinib works by inhibiting the IGF-1R target, which is the only validated clinical target in TED and the only target for current FDA-approved therapies. Activation of the IGF-1R target leads to inflammation and proptosis seen in TED. Linsitinib has an established safety profile through treatment of more than 900 patients in fifteen clinical trials in multiple diseases. About Thyroid Eye Disease (TED) Thyroid Eye Disease (TED) is a serious, progressive, and vision-threatening rare autoimmune disease that affects approximately 70,000 people in the U.S. and has a similar prevalence in the EU. TED often occurs in people living with Graves' disease and hyperthyroidism and is caused by dysfunction in the IGF-1R signaling pathway which results in fibrous tissue growth behind the eyes. This leads to several negative symptoms that may have long-term, irreversible damage as the tissue growth pushes the eyes forward or causes the eyes and eyelids to become red and swollen. As the disease progresses it can lead to pain, eye bulging (proptosis), and double vision (diplopia), thus dramatically impacting a patient's quality of life. TED predominantly affects women, and most frequently affects people with hyperthyroidism due to Graves' disease. Current standard of care typically involves either invasive orbital surgery or a lengthy series of infusions with potential adverse events like loss of hearing, hyperglycemia or menstrual cycle changes. About Sling Therapeutics Sling Therapeutics, Inc., is a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED). The company's lead product candidate, linsitinib, works by inhibiting the validated IGF-1R target. It recently completed a Phase 2b/3 clinical trial for the treatment of TED and is on target for initiating its confirmatory Phase 3 trial in 2025. Based on extensive preclinical and clinical data from more than 900 patients, linsitinib offers the potential of a convenient oral small molecule that could significantly reduce the treatment burden for people living with TED while improving and simplifying patient care by physicians and hospitals. For more information, please visit or follow us on LinkedIn or X (formerly known as Twitter). Investor and Media Contact: Argot Partners (212) 600-1902 [email protected] SOURCE Sling Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3

14 Jan 2025

·endpts.com

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan

Plus, news about Bioptimus, RhyGaze, Grifols, subcutaneous Leqembi and Sling Therapeutics: Regeneron pours $119.5M into Truveta Series C: Regeneron will also work with the medical data research company to launch a genome project that aims to sequence ten million patient volunteers. Illumina is also investing $20 million into the Series C. – Ayisha Sharma Inhibrx Bio inks loan facility for up to $150M: The funding should give the San Diego-based biotech “strategic flexibility” beyond anticipated data readouts later this year for two of its programs — INBRX-109 and INBRX-106. Inhibrx has so far received an initial $100 million from the five-year term agreement with Oxford Finance. – Ayisha Sharma Bioptimus gets $41M in new financing: The raise brings the company’s total amount to $76 million after it debuted last February with a $35 million seed round. Bioptimus will use the money to “enhance its multi-modal AI platform,” it said in a press release, which may include the ability to sign partnerships with biopharma companies. — Max Gelman Ophthalmic biotech secures $86M in Series A: Basel-based RhyGaze plans to use the proceeds to advance its lead gene therapy candidate designed to restore vision in diseases that cause blindness. Google Ventures led the fundraise, with support from the likes of Novartis Venture Fund and ARCH Venture Partners. – Ayisha Sharma Grifols gets $21M grant for Parkinson’s research: The company received the grant from the Michael J. Fox Foundation for Parkinson’s Research. It will fund a pilot study to analyze plasma samples from Parkinson’s patients for up to 10 years, which the company hopes will help bring about better diagnostic tools and therapeutics for patients. — Max Gelman FDA accepts BLA for subcutaneous Leqembi: Eisai and Biogen are seeking approval for the amyloid-targeting antibody as a weekly maintenance therapy in early Alzheimer’s disease. The agency will issue a decision by Aug. 31. — Elizabeth Cairns Sling’s thyroid eye disease pill hits: The IGF-1R inhibitor linsitinib reduced proptosis (eye bulging) in 52% of Phase 2b/3 trial subjects given the higher 150 mg twice-daily dose for six months. Sling did not give details for the 75 mg dose, but said the drug was well-tolerated. A pivotal Phase 3 trial is expected to start this year. — Elizabeth Cairns

Phase 3Gene Therapy

100 Deals associated with Linsitinib

External Link

KEGG	Wiki	ATC	Drug Bank
D09925	Linsitinib	-	DB06075

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adrenocortical Carcinoma	Phase 2	CA	Astellas Pharma, Inc.	01 Dec 2009
Adrenocortical Carcinoma	Phase 2	PL	Astellas Pharma, Inc.	01 Dec 2009
Adrenocortical Carcinoma	Phase 2	AU	Astellas Pharma, Inc.	01 Dec 2009
Adrenocortical Carcinoma	Phase 2	AU	Astellas Pharma, Inc.	01 Dec 2009
Adrenocortical Carcinoma	Phase 2	PL	Astellas Pharma, Inc.	01 Dec 2009
Adrenocortical Carcinoma	Phase 2	CA	Astellas Pharma, Inc.	01 Dec 2009
Adrenocortical Carcinoma	Phase 2	NL	Astellas Pharma, Inc.	01 Dec 2009
Adrenocortical Carcinoma	Phase 2	NL	Astellas Pharma, Inc.	01 Dec 2009
Adrenocortical Carcinoma	Phase 2	US	Astellas Pharma, Inc.	01 Dec 2009
Adrenocortical Carcinoma	Preclinical	US	Astellas Pharma, Inc.	01 Dec 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ENDO2024	Not Applicable	IGF-1R \| TSH-R	-	Linsitinib	efpfknndre(wpmkmbpmsj) = gvuzwqysan jctcrhdpib (axemwpwepf ) View more	Positive	01 Jun 2024
				Teprotumumab	efpfknndre(wpmkmbpmsj) = bpdiksnjss jctcrhdpib (axemwpwepf ) View more
NCT01560260 (SARC, Pubmed \| Clin Cancer Res) Manual	Phase 2	Gastrointestinal Stromal Tumors	20	Linsitinib	(pmzwrfrmhz) = kfrltywthm iajwgrxijf (dfjpjedxjr ) View more	Positive	15 Apr 2020
NCT01186861 (Pubmed \| Med J Aust) Manual	Phase 2	Non-Small Cell Lung Cancer Maintenance	205	erlotinib+linsitinib	(bhgubdmirj): P-Value = 0.601 View more	Negative	05 Sep 2017
				erlotinib+Placebo
NCT01560260 (SARC, CTgov)	Phase 2	Paraganglioma \| Chondrosarcoma \| Gastrointestinal Stromal Tumors \| Carney Complex	20	Pharmacological Study+Linsitinib	fageogozsn(pywiuplxrn) = kcfirobaqc kiekhycifi (fkmdmnthju, aohgkkxkxo - tokthnvmws) View more	-	19 Jan 2017
NCT01221077 (Pubmed \| Clin Lung Cancer) Manual	Phase 2	Non-Small Cell Lung Cancer	88	erlotinib+Linsitinib	(gqyrmjhaqr) = noqvqqscdz nlbqqtegyc (clyippfouc ) View more	Negative	01 Jan 2017
				erlotinib+Placebo	(gqyrmjhaqr) = uhuqhjwems nlbqqtegyc (clyippfouc ) View more
NCT00739453 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Advanced Malignant Solid Neoplasm	95	Linsitinib+Erlotinib (Advanced Solid Tumors)	(uaxoffxmig) = On the basis of prior monotherapy data, S3 dosing at 150 mg twice daily/150 mg once daily was the recommended phase II dose for the expansion cohort. neybqrjeqb (vdktistknf ) View more	Positive	15 Jun 2016
				Linsitinib+Erlotinib (non-small cell lung cancer (NSCLC))
NCT01533181 (CTgov)	Phase 2	Recurrent Lung Small Cell Carcinoma	44	Topotecan (Arm A: Topotecan)	(nlbfuxkqtk) = lqfxrchotr cypfjbwugl (wgufsuonbg, cgprzecjiq - eprsdztnyq) View more	-	14 Jan 2016
				OS-906 (Arm B: OS-906)	(nlbfuxkqtk) = jexsqfjsvr cypfjbwugl (wgufsuonbg, zaoxvcfdwe - gtblbggfau) View more
NCT00924989 (Pubmed \| Lancet Oncol) Manual	Phase 3	Adrenocortical Carcinoma	139	Linsitinib	(lfjhoownnf) = rvcvlrnuqe btctorguxx (vfqyhbkmzy )	Negative	01 Apr 2015
				Placebo	(lfjhoownnf) = ooqjqbxyjw btctorguxx (vfqyhbkmzy ) View more
NCT01533246 (CTgov)	Phase 2	Recurrent Prostate Carcinoma \| Metastatic Prostate Carcinoma \| Metastatic castration-resistant prostate cancer \| Adenocarcinoma of prostate	17	laboratory biomarker analysis+linsitinib	xvjzrtxwlw(hytvgskgbo) = msedbzqapi rediybncvf (fhycmavdld, cbgymnfgzd - fzvdltobyw) View more	-	13 Mar 2015
NCT00514007 (Pubmed \| Clin Cancer Res) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	95	OSI-906	(qocyenbtzn) = 400 mg once daily and 150 mg twice daily fxuaiynxgt (jbbthagvwc ) View more	Positive	15 Feb 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis